All In Biotech

Drug Trial Radar · NCT05963997

A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer

A Phase 1b/2 Open-label Study of Samuraciclib in Combination With Elacestrant in Participants With Metastatic or Locally Advanced Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Breast Cancer

Last checked: Nov 19, 2026Latest source record: Mar 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

49

Actual

Start

Oct 9, 2023

Primary completion

Mar 6, 2026

Study completion Mar 6, 2026

Sponsor

Lead sponsor
Carrick Therapeutics LimitedIndustry
Sponsor type
Industry
Collaborators
Berlin-Chemie AG Menarini Group
First posted
Jul 27, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an international, multisite, open-label, Phase 1b/2 study, to confirm safety and efficacy of samuraciclib in combination with elacestrant in adult participants with metastatic or locally advanced Hormone Receptor (HR) positive and Human Epidermal Growth Factor Receptor (HER)2-negative breast cancer.

Conditions

  • Metastatic Breast Cancer
  • Locally Advanced Breast Cancer
  • Breast Cancer

Interventions

  • SamuraciclibDrug

    Samuraciclib capsules by mouth once a day

  • Elacestrant DihydrochlorideDrug

    Elacestrant tablets by mouth once a day

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1b (Dose-finding)Time frame: From the date of first dose of any study intervention (Day 1 Cycle 1) and through 28 days after the last dose of any study intervention
  2. Phase 2 (Expansion)Time frame: From the date of first dose of any study intervention (Cycle 1 Day 1) until the first documentation of disease progression, death, withdrawal of consent, or start of new anticancer therapy (assessed up to week 48)

Locations

23 sites in 4 countries. Site status is shown where the registry gives one.

  • Site 38 - Northwestern University, Feinberg School of Medicine, Northwestern University

    Chicago, Illinois

  • Site 42 - Dana-Farber Cancer Institute, EDDC

    Boston, Massachusetts

  • Site 35 - Cleveland Clinic, Taussig Cancer Institute

    Cleveland, Ohio

  • Site 41 - The START Center for Cancer Care, South Texas Oncology and Hematology

    San Antonio, Texas

  • Site 32 - Swedish Medical Center, Swedish Cancer Institute (SCI),Cherry Hill Campus

    Seattle, Washington

  • Site 81 - Bergonie unicancer, Nouvelle-Aquitaine, L'Institut Bergonie

    Bordeaux, France

  • Site 80 - Centre Jean Bernard, Clinique Victor Hugo

    Le Mans, France

  • Site 83 - Institut Paoli Calmettes (IPC)

    Marseille, France

  • Site 85 - Institut Curie

    Paris, France

  • Site 82 - Institut de Cancerologie de Ouest (ICO)

    Saint-Herblain, France

  • Site 65 - Complexo Hospitalario Universitario A Coruña

    A Coruña, Spain

  • Site 64 - Hospital Clinic de Barcelona (Hospital Clinic i Provincial)

    Barcelona, Spain

  • Site 68 -Hospital Universitario Vall d'Hebron

    Barcelona, Spain

  • Site 61 - Institut Catala d'Oncologia (ICO), Hospital Duran i Reynals Location

    L'Hospitalet de Llobregat, Spain

  • Site 62 - Universidad de Navarra, Clinica Universidad de Navarra (CUN)

    Madrid, Spain

  • Site 63 - South Texas Accelerated Research Therapeutics, CIOCC, Hospital Madrid Norte-Sanchinarro

    Madrid, Spain

  • Site 66 - Hospital Clinico San Carlos

    Madrid, Spain

  • Site 69 - Universidad de Navarra - Clinica Universidad de Navarra (CUN)

    Pamplona, Spain

  • Site 60 - NEXT Oncology EU Hospital Universitario Quiron Salud Madrid

    Pozuelo de Alarcón, Spain

  • Site 67 - Universidad de Sevilla, Hospital Universitario Virgen Macarena

    Seville, Spain

  • Site 12 - Belfast City Hospital

    Belfast, United Kingdom

  • Site 4 - The Christie NHS Foundation Trust

    Manchester, United Kingdom

  • Site 2 - Oxford University Hospitals NHS Trust - Churchill Hospital

    Oxford, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.